Cisterna Biologics
Cisterna Biologics enhances mRNA quality for therapeutics using proprietary tech.
Cisterna Biologics enhances mRNA quality for therapeutics using proprietary tech.
Founded in 2022 and based in San Diego, California, Cisterna Biologics is dedicated to advancing mRNA-based therapeutics. The company's core mission is to address critical challenges in the biotech industry related to the quality, quantity, longevity, and cost of mRNA. Cisterna Biologics utilizes proprietary technologies to enhance mRNA quality, aiming to unlock the full potential of mRNA as a therapeutic tool. Their market focus includes pharmaceutical companies and research institutions seeking high-quality mRNA solutions.
Cisterna Biologics has attracted notable investors and industry experts who recognize the transformative potential of their technology. While specific names are not disclosed, the company's innovative approach has garnered attention within the biotech community. Key achievements include the development of proprietary methods that significantly improve mRNA purity and stability. Cisterna Biologics' impact is seen in its contribution to making mRNA-based treatments more viable and accessible, potentially revolutionizing therapeutic applications.
Companies similar to Cisterna Biologics include Sensible Biotechnologies, ParcelBio, Serna Bio and Rnaimmune.
Cisterna Biologics was founded in 2022.
Cisterna Biologics' headquarters is located in Carlsbad, CA, US.
Cisterna Biologics' most recent funding round was for $500k (USD) in August 2022.
As of Aug 22, 2022, Cisterna Biologics has disclosed funding of $500k (USD). Undisclosed round amounts are excluded.
Cisterna Biologics has 2 employees as of Apr 6, 2024.
Rnaimmune
rnaimmune.com
